GLPwatch
Papers (10389)
Page 146 of 174, ranked by citation count.
- Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.
- Effect of Peptide Drug Liraglutide Nano-Formulation Combined with Sodium-Glucose Cotransporter-2 Inhibitor on Blood Lipids in Patients with Type 2 Diabetes.
- In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
- Tirzepatide associated autoimmune encephalitis: A case report.
- Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.
- [Benefits of telematic monitoring for weight loss in overweight and obese patients in times of confinement].
- Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management.
- [Incretin analogues as a novel treatment strategy for Alzheimer's disease].
- Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
- Semaglutide and Cardiovascular Outcomes.
- Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes.
- EHR Data Suggest Tirzepatide Outdoes Semaglutide for Weight Loss.
- The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care.
- Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings.
- Liraglutide effect on epicardial fat: Missing the forest for the trees.
- Adverse events associated with tirzepatide: a focus on subgroup-specific differences.
- The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.
- Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.
- Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.
- Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model.
- Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment.
- Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
- Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning.
- Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss.
- Recent diabetes issues affecting the primary care clinician.
- Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.
- Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.
- Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews.
- The revolution of the anti-diabetic drugs in cardiology.
- In brief: Semaglutide (Wegovy) for weight loss in children.
- Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
- Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.
- Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.
- In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.
- Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.
- Dulaglutide plus dapaglifozin use until the second trimester of pregnancy in a woman with type 2 diabetes.
- Once-weekly glucagon-like peptide 1 receptor agonists.
- Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large.
- Exendin-4 Prevents oxLDL-Induced upregulation of TREM2 and attenuates foam cell formation and inflammation in Macrophages.
- A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C.
- The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.
- Efficacy and safety of semaglutide in a diabetic and obese patient on incremental hemodialysis. Does it also contribute to preserving residual renal function?
- Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
- Effects of liraglutide on the testis of rats with experimental diabetes and ischemia-reperfusion injury.
- Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.
- GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.
- Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.
- [Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review].
- Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment.
- Tirzepatide vs. Semaglutide for Obesity Treatment.
- Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More.
- Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.
- Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation.
- Injectable drugs for weight management.
- The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS.
- Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
- Trends and Disparities in Newer GLP1 Receptor Agonist Initiation among Real-World Adult Patients Eligible for Obesity Treatment.
- FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.
- Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice.